Payment overview · 2025
General Payments
$780.59
40 reported records · 14 companies
Healthcare provider profile · identity verified
Jay E Endres, MD
Allopathic & Osteopathic Physicians|Internal Medicine · WARREN, PA · NPI 1073581948
Verified facts
What the public records show
CMS Open Payments records show Jay E Endres, MD received $780.59 in general payments during 2025 across 40 reported records.
AstraZeneca Pharmaceuticals LP accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Farxiga, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 166 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 175 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 877 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $248.58 | 31.9% | 8 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $101.22 | 13.0% | 6 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $94.87 | 12.2% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $78.36 | 10.0% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $71.70 | 9.2% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $47.89 | 6.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.86 | 2.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $21.60 | 2.8% | 1 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $17.96 | 2.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.39 | 2.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.10 | 2.1% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $15.89 | 2.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $13.62 | 1.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.55 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $780.59 | 40 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $142.42 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $94.87 | 6 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $85.54 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $85.54 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $71.70 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $67.97 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.77 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.89 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.64 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.59 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.22 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 16 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 877 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 70 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 49 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 106 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 175 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
16 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
166 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
106 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
175 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
877 | 100 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1664 | 172 |
| Potassium Chloride | Potassium Chloride | 1354 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 1348 | 177 |
| Lisinopril | Lisinopril | 1307 | 171 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1019 | 186 |
| Tramadol Hcl | Tramadol Hcl | 980 | 86 |
| Furosemide | Furosemide | 887 | 99 |
| Sertraline Hcl | Sertraline Hcl | 882 | 81 |
| Eliquis | Apixaban | 877 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 838 | 136 |
| Famotidine | Famotidine | 796 | 63 |
| Metoprolol Tartrate | Metoprolol Tartrate | 683 | 98 |
| Bumetanide | Bumetanide | 669 | 72 |
| Gabapentin | Gabapentin | 665 | 69 |
| Donepezil Hcl | Donepezil Hcl | 664 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 662 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 588 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 586 | 31 |
| Metformin Hcl | Metformin Hcl | 552 | 87 |
| Duloxetine Hcl | Duloxetine Hcl | 494 | 42 |
| Lorazepam | Lorazepam | 482 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 472 | 60 |
| Losartan Potassium | Losartan Potassium | 458 | 59 |
| Memantine Hcl | Memantine Hcl | 421 | 25 |
| Omeprazole | Omeprazole | 388 | 86 |
| Mirtazapine | Mirtazapine | 379 | 41 |
| Buspirone Hcl | Buspirone Hcl | 375 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 371 | 30 |
| Simvastatin | Simvastatin | 355 | 66 |
| Xarelto | Rivaroxaban | 326 | 42 |
| Trazodone Hcl | Trazodone Hcl | 304 | 39 |
| Atenolol | Atenolol | 259 | 25 |
| Levetiracetam | Levetiracetam | 257 | 21 |
| Myrbetriq | Mirabegron | 255 | 24 |
| Meloxicam | Meloxicam | 253 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 51 |
| Fluoxetine Hcl | Fluoxetine Hcl | 217 | 28 |
| Citalopram Hbr | Citalopram Hydrobromide | 210 | 20 |
| Carvedilol | Carvedilol | 192 | 22 |
| Aripiprazole | Aripiprazole | 177 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 176 | 13 |
| Allopurinol | Allopurinol | 175 | 26 |
| Rexulti | Brexpiprazole | 175 | 18 |
| Prednisone | Prednisone | 170 | 22 |
| Trulicity | Dulaglutide | 166 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 165 | 32 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 162 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 159 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 156 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 155 | 30 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 152 | 53 |
| Paroxetine Hcl | Paroxetine Hcl | 151 | 13 |
| Alprazolam | Alprazolam | 145 | 15 |
| Cephalexin | Cephalexin | 145 | 47 |
| Entresto | Sacubitril/Valsartan | 145 | 14 |
| Lamotrigine | Lamotrigine | 141 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 141 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 137 | 77 |
| Olanzapine | Olanzapine | 137 | 14 |
| Midodrine Hcl | Midodrine Hcl | 136 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 135 | 19 |
| Baclofen | Baclofen | 131 | 13 |
| Warfarin Sodium | Warfarin Sodium | 126 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 125 | 14 |
| Sucralfate | Sucralfate | 122 | 12 |
| Finasteride | Finasteride | 112 | 13 |
| Montelukast Sodium | Montelukast Sodium | 109 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 109 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 108 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 107 | 46 |
| Ondansetron Hcl | Ondansetron Hcl | 106 | 44 |
| Ozempic | Semaglutide | 106 | 19 |
| Alendronate Sodium | Alendronate Sodium | 105 | 25 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 101 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 22 |
| Risperidone | Risperidone | 97 | suppressed |
| Fentanyl | Fentanyl | 96 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 95 | suppressed |
| Nystatin | Nystatin | 92 | 53 |
| Primidone | Primidone | 90 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 85 | 17 |
| Clonazepam | Clonazepam | 81 | suppressed |
| Spironolactone | Spironolactone | 79 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 78 | 20 |
| Meclizine Hcl | Meclizine Hcl | 78 | 11 |
| Methocarbamol | Methocarbamol | 78 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 77 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 76 | 13 |
| Labetalol Hcl | Labetalol Hcl | 73 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 70 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 69 | 15 |
| Propranolol Hcl | Propranolol Hcl | 69 | suppressed |
| Amoxicillin | Amoxicillin | 67 | 28 |
| Clonidine Hcl | Clonidine Hcl | 67 | 24 |
| Topiramate | Topiramate | 66 | suppressed |
| Januvia | Sitagliptin Phosphate | 65 | suppressed |
| Latanoprost | Latanoprost | 65 | 15 |
| Methylprednisolone | Methylprednisolone | 65 | 55 |
| Azithromycin | Azithromycin | 64 | 42 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 62 | 18 |
| Cefdinir | Cefdinir | 61 | 44 |
| Humalog Kwikpen U-100 | Insulin Lispro | 61 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 61 | 32 |
| Ceftriaxone | Ceftriaxone Sodium | 59 | 28 |
| Digoxin | Digoxin | 59 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 58 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 58 | suppressed |
| Ezetimibe | Ezetimibe | 57 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 56 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 28 |
| Lovastatin | Lovastatin | 56 | 15 |
| Pilocarpine Hcl | Pilocarpine Hcl | 56 | suppressed |
| Verapamil Sr | Verapamil Hcl | 55 | suppressed |
| Amantadine | Amantadine Hcl | 53 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | suppressed |
| Mupirocin | Mupirocin | 53 | 31 |
| Hydrocortisone | Hydrocortisone | 52 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 52 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 51 | suppressed |
| Fluconazole | Fluconazole | 50 | 24 |
| Mirabegron Er | Mirabegron | 50 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 50 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 49 | 20 |
| Lidocaine Hcl | Lidocaine Hcl | 49 | 25 |
| Mounjaro | Tirzepatide | 49 | suppressed |
| Synthroid | Levothyroxine Sodium | 49 | 12 |
| Diazepam | Diazepam | 48 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 47 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | suppressed |
| Phenytoin | Phenytoin | 46 | suppressed |
| Pregabalin | Pregabalin | 46 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 45 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 44 | suppressed |
| Trospium Chloride | Trospium Chloride | 44 | suppressed |
| Valsartan | Valsartan | 43 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 12 |
| Carbamazepine | Carbamazepine | 41 | suppressed |
| Humalog | Insulin Lispro | 41 | suppressed |
| Modafinil | Modafinil | 41 | suppressed |
| Scopolamine | Scopolamine | 41 | 14 |
| Telmisartan | Telmisartan | 41 | suppressed |
| Folic Acid | Folic Acid | 40 | suppressed |
| Lactulose | Lactulose | 40 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 39 | suppressed |
| Ranolazine Er | Ranolazine | 39 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 38 | suppressed |
| Nyamyc | Nystatin | 38 | 17 |
| Nystop | Nystatin | 38 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 36 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 36 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 36 | suppressed |
| Nifedipine Er | Nifedipine | 35 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 34 | suppressed |
| Lumigan | Bimatoprost | 34 | suppressed |
| Methotrexate | Methotrexate Sodium | 34 | suppressed |
| Tradjenta | Linagliptin | 34 | suppressed |
| Acyclovir | Acyclovir | 33 | 15 |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Gemfibrozil | Gemfibrozil | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 33 | 31 |
| Anastrozole | Anastrozole | 32 | suppressed |
| Celecoxib | Celecoxib | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 31 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 31 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 31 | 23 |
| Ibuprofen | Ibuprofen | 30 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 28 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 25 | suppressed |
| Nateglinide | Nateglinide | 25 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 25 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 24 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 24 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 24 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Gemtesa | Vibegron | 23 | suppressed |
| Klor-Con M10 | Potassium Chloride | 23 | 11 |
| Lacosamide | Lacosamide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 22 | suppressed |
| Loperamide | Loperamide Hcl | 21 | 12 |
| Ventolin Hfa | Albuterol Sulfate | 21 | 12 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 20 | suppressed |
| Admelog | Insulin Lispro | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Haloperidol | Haloperidol | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Jantoven | Warfarin Sodium | 19 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 19 | suppressed |
| Rybelsus | Semaglutide | 19 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Jardiance | Empagliflozin | 17 | suppressed |
| Ketoconazole | Ketoconazole | 17 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 16 | 15 |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 16 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Leflunomide | Leflunomide | 15 | suppressed |
| Levocarnitine | Levocarnitine | 15 | suppressed |
| Paliperidone Er | Paliperidone | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 11 | suppressed |
| Clobazam | Clobazam | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Ivermectin | Ivermectin | 11 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Olanzapine Odt | Olanzapine | 11 | suppressed |
| Ropinirole Er | Ropinirole Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $780.59 · 40 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FREESTYLE LIBRE 3, INGREZZA, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, PAXLOVID, PROLIA, REXULTI, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error